A practical reference on receptor agonist: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Receptor activation occurs at GLP-1 receptors distributed across pancreatic islets, the hypothalamus, and the gastrointestinal tract. Binding triggers G protein signaling that raises cyclic AMP and enhances glucose-dependent insulin release. Because the effect depends on prevailing glucose levels, insulin secretion does not rise when blood sugar is already low. Signaling in the brain and gut also influences appetite and gastric emptying, which is why the compound appears in both metabolic and weight-related research literature.
Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.
Native GLP-1 is degraded rapidly by dipeptidyl peptidase-4. Semaglutide resists this cleavage because alanine at position 8 is replaced by alpha-aminoisobutyric acid. A second substitution at position 34 introduces arginine, which further stabilizes the peptide. The most distinctive modification is a spacer and C18 fatty diacid attached at lysine 26, enabling strong albumin affinity. These three changes together produce a half-life measured in days rather than minutes, and the same structural logic underlies other long-acting analogs in this class.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L-cells after food intake. It contains 31 amino acids and differs from native GLP-1 through modifications that slow enzymatic breakdown. The peptide was developed to extend the short circulating half-life of endogenous GLP-1, which is measured in minutes. Researchers introduced the compound in the early 2010s. Two backbone changes and a fatty acid side chain define its structure, distinguishing it from earlier GLP-1 receptor agonists.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide, GLP-1 receptor agonist | Not a small molecule |
| Backbone substitutions | Non-natural residue at position 8, arginine at position 34 | Slows enzymatic cleavage |
| Side chain | C18 fatty diacid with PEG linker | Enables albumin binding |
| Approximate molecular mass | 4114 Da | Varies slightly with salt form |
| Reported half-life | About one week | Longer than native GLP-1 by orders of magnitude |
GLP-1 receptors are expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises cyclic AMP, enhances glucose-dependent insulin secretion, and suppresses glucagon release when blood glucose is high. Effects on gastric emptying and on hypothalamic appetite circuits reduce energy intake. Because insulin release remains glucose-dependent, the risk of hypoglycemia is low when the drug is used alone. The precise contribution of each pathway to body weight change in humans remains an area of active investigation.
Clinical studies of semaglutide generally measure glycated hemoglobin, fasting plasma glucose, body weight, and composite cardiovascular endpoints. The SUSTAIN program enrolled adults with type 2 diabetes, while the STEP program focused on obesity without diabetes. Administration follows a stepwise escalation schedule designed to limit gastrointestinal effects during the first weeks. Reported outcomes include mean percentage weight change, the proportion of participants reaching defined weight-loss thresholds, and rates of nausea, vomiting, and diarrhea. Long-term data on durability after treatment stops are still limited and remain a topic of ongoing research.
关于降解产物的免疫原性风险，文献中仍有讨论空间。体外聚集水平与临床免疫反应之间的定量关系尚未确立。多数公开研究只报告理化指标，缺少长期随访的对应数据。这一问题在生物类似物比对中尤其受到关注。
市售注射用制剂通常要求在二至八摄氏度冷藏保存，并避免光照与冻结。部分多剂量笔在首次使用后允许在不超过三十摄氏度的环境中存放有限周数，具体期限由辅料与防腐剂体系决定。反复冻融会促进肽链聚集并改变可见颗粒计数，因此应予避免。冻干粉末在干燥、避光、低温条件下更为稳定。溶液配制后宜使用低吸附容器，以减少肽类在塑料或玻璃表面的损失。
Solid peptide material is generally kept at reduced temperature to limit degradation. Short-term storage at 2 to 8 degrees Celsius is common, while longer archival storage at minus 20 degrees Celsius or below is typical for lyophilised powder. Vials should remain sealed and protected from light, because ultraviolet exposure can oxidise susceptible residues. Repeated freeze-thaw cycles are avoided, as they promote aggregation and loss of soluble material. Solutions are less stable than solids and are usually prepared close to the time of use.
Reversed-phase high-performance liquid chromatography is widely used to assess purity and to separate the parent peptide from related substances. Mass spectrometry confirms identity and can resolve modifications that differ by a few daltons. Size-exclusion chromatography detects dimers and higher aggregates, which are relevant to both stability and immunogenicity questions. Peptide mapping with enzymatic digestion locates specific modifications along the sequence. Circular dichroism provides a secondary-structure profile, although it gives limited information about local conformational changes.
Quality control for peptide material focuses on identity, purity, content and the profile of impurities. Common degradants include deamidated and oxidised forms, plus aggregates formed during storage or handling. Forced degradation studies under heat, light, acid and peroxide help define which conditions accelerate change and which analytical methods detect it. Limits for individual impurities are set by pharmacopoeial monographs or manufacturer specifications. How much a given impurity affects biological activity is often uncertain, and conclusions may depend on the assay used.
The number of subunits in an oligomeric complex is described using names that end in -mer (Greek for "part, subunit"). Formal and Greco-Latinate names are generally used for the first ten types and can be used for up to twenty subunits, whereas higher order complexes are usually described by the number of subunits, followed by -meric.
== Metabolism == The kinin–kallikrein system makes bradykinin by proteolytic cleavage of its kininogen precursor, high-molecular-weight kininogen (HMWK or HK), by the enzyme kallikrein. Moreover, there is evidence that plasmin, a fibrinolytic enzyme, is able to generate bradykinin after HMWK cleavage. In humans, bradykinin is broken down by many different kininases: angiotensin-converting enzyme (ACE, kininase II), neprilysin, NEP2, aminopeptidase P (APP), carboxypeptidase N (CPN, kininase I), Carboxypeptidase M, Neutral endopeptidase 24.15, Endothelin converting enzyme-1, Endothelin converting enzyme-2.
Opioids by mouth, including both weak opioids such as tramadol and stronger opioids, are also often prescribed. Their appropriateness is uncertain, and opioids are often recommended only when first-line therapies have failed or are contraindicated. This is due to their small benefit and relatively large risk of side effects. The use of tramadol likely does not improve pain or physical function and likely increases the incidence of adverse side effects. Oral steroids are not recommended in the treatment of osteoarthritis. Use of the antibiotic doxycycline orally for treating osteoarthritis is not associated with clinical improvements in function or joint pain and long term use is associated with a high risk of side effects. A 2018 meta-analysis found that oral collagen supplementation for the treatment of osteoarthritis reduces stiffness, but does not improve pain and functional limitation.
=== Salvage pathways === Despite the presence of the de novo pathway, the salvage reactions are essential in humans; a lack of vitamin B3 in the diet causes the vitamin deficiency disease pellagra. This high requirement for NAD+ results from the constant consumption of the coenzyme in reactions such as posttranslational modifications, since the cycling of NAD+ between oxidized and reduced forms in redox reactions does not change the overall levels of the coenzyme. The major source of NAD+ in mammals is the salvage pathway which recycles the nicotinamide produced by enzymes utilizing NAD+. The first step, and the rate-limiting enzyme in the salvage pathway is nicotinamide phosphoribosyltransferase (NAMPT), which produces nicotinamide mononucleotide (NMN). NMN is the immediate precursor to NAD+ in the salvage pathway. Besides assembling NAD+ de novo from simple amino acid precursors, cells also salvage preformed compounds containing a pyridine base. The three vitamin precursors used in these salvage metabolic pathways are nicotinic acid (NA), nicotinamide (Nam) and nicotinamide riboside (NR). These compounds can be taken up from the diet and are termed vitamin B3 or niacin. However, these compounds are also produced within cells and by digestion of cellular NAD+. Some of the enzymes involved in these salvage pathways appear to be concentrated in the cell nucleus, which may compensate for the high level of reactions that consume NAD+ in this organelle.
== Interactions == Some of the drugs that frequently interact with modafinil include aripiprazole (an antipsychotic), amphetamine (including its enantiomers and salts; stimulants), and others. Modafinil is a weak to moderate inducer of CYP3A4 and a weak inhibitor of CYP2C19, enzymes of the cytochrome P450 system. Modafinil also induces or inhibits other cytochrome P450 enzymes. One in vitro study predicts that modafinil may induce the cytochrome P450 enzymes CYP1A2, CYP3A4, and CYP2B6, as well as may inhibit CYP2C9 and CYP2C19. However, other in-vitro work has shown no significant inhibition of CYP2C9. Modafinil may induce P-glycoprotein, which may affect drugs transported by P-glycoprotein, such as digoxin. In clinical use, modafinil affects the pharmacodynamics of drugs metabolized by CYP3A4 and other cytochrome P450 enzymes, with these interactions observed in patients. For instance, CYP3A4 induction by modafinil can reduce plasma concentrations of opioids such as methadone, hydrocodone, oxycodone, and fentanyl, potentially causing reduced efficacy or withdrawal symptoms. Modafinil also affects steroid hormones, including estradiol, progesterone, and cortisol, and can reduce the effectiveness of hormonal contraceptives for up to a month after discontinuation. Since modafinil induces the activity of the CYP3A4 enzyme involved in cortisol clearance, modafinil may reduce the bioavailability of hydrocortisone. Therefore, it may be necessary to adjust the steroid substitution dose in people receiving modafinil, which is a CYP3A4-metabolism-inducing drug.
Sources: en.wikipedia.org
=== 16 January === Senior US officials reported that the SAF had recently used chemical weapons against the RSF in rural areas at least twice. The US also sanctioned SAF chief General Abdel Fattah al-Burhan for the army's conduct in the war. The RSF said that it attacked fighters and vehicles in Kabkabiya belonging to the JDF between the SLM-Al Nur and the GSLF. The RSF called for a joint committee to investigate the incident.
Poultices are used on horses to relieve inflammation. Usually applied to the lower legs, under a stable bandage, to focus treatment on the easily injured tendons in the area. Poultices are sometimes applied as a precautionary measure after the horse has worked hard, such as after racing, jumping, or cross-country riding, to forestall strains or stiffness. They may be used to treat abscesses, with the intention of drawing out pus from the wound. Cooling poultices are sometimes used for show-jumpers and racehorses; these may be cheaper and easier to administer than commercial cooling products. A poultice is applied to the horse's distal limbs after exercise, for 9–12 hours. The intended effect is to cool the legs over a long period of time, by dispersing heat from the limb through the action of evaporation. Commonly, the poultice is bandaged over, sometimes with materials such wet newspaper between the poultice and bandages; this greatly reduces evaporation and heat loss, rendering the poultice ineffective at cooling.
Portable water purification devices are self-contained, easily transported units used to purify water from untreated sources (such as rivers, lakes, and wells) for drinking purposes. Their main function is to eliminate pathogens, and often also suspended solids and some unpalatable or toxic compounds. These units provide an autonomous supply of drinking water to people without access to clean water supply services, including inhabitants of developing countries and disaster areas, military personnel, campers, hikers, and workers in wilderness, and survivalists. They are also called point-of-use water treatment systems and field water disinfection techniques. Techniques include heat (including boiling), filtration, activated charcoal adsorption, chemical disinfection (e.g. chlorination, iodine, ozonation, etc.), ultraviolet purification (including sodis), distillation (including solar distillation), and flocculation. Often these are used in combination.
On 12–13 December 1981, the regime declared martial law in Poland, under which the army and the ZOMO special police forces were used to crush Solidarity. The Soviet leaders insisted that Jaruzelski pacifies the opposition with the forces at his disposal, without Soviet involvement. Almost all Solidarity leaders and many affiliated intellectuals were arrested or detained. Nine workers were killed in the Pacification of Wujek. The United States and other Western countries responded by imposing economic sanctions against Poland and the Soviet Union. Unrest in the country was subdued, but continued. During martial law, Poland was ruled by the so-called Military Council of National Salvation. The open or semi-open opposition communications, as recently practiced, were replaced by underground publishing (known in the eastern bloc as Samizdat), and Solidarity was reduced to a few thousand underground activists. Having achieved some semblance of stability, the Polish regime relaxed and then rescinded martial law over several stages. By December 1982 martial law was suspended and a small number of political prisoners, including Wałęsa, were released. Although martial law formally ended in July 1983 and a partial amnesty was enacted, several hundred political prisoners remained in jail. Jerzy Popiełuszko, a popular pro-Solidarity priest, was abducted and murdered by security functionaries in October 1984.
Sources: en.wikipedia.org
Native GLP-1 is degraded within minutes by circulating enzymes. The synthetic version carries substitutions at positions that block enzymatic cleavage, plus a fatty acid side chain that promotes albumin binding. These two changes together extend circulation time from minutes to roughly a week.
Albumin binding keeps a large fraction of the compound in a slowly released reservoir within the bloodstream. Plasma levels decline gradually rather than falling sharply after each administration. That profile supports dosing intervals measured in days instead of hours.
The active peptide sequence is the same in both formats. The oral version adds an absorption enhancer that is not present in the injected solution. Differences in excipients and formulation affect uptake rather than the identity of the active molecule.
It is a synthetic analog of GLP-1 produced through medicinal chemistry to resist enzymatic degradation. The design goal was longer circulation than the native hormone.